ARTICLES BY THIS AUTHOR
- 9/5/2011
Evidence strongest for epinephrine in anaphylaxis Rx
Second-line drugs need more study: Simons - 9/5/2011
Azathioprine eyed for liver toxicity risk in rheumatoid arthritis patients
Hospitalization for acute hepatotoxicity among rheumatoid arthritis patients appears to be related to previous liver disease as well as treatment with the immunosuppressant azathioprine, Canadian researchers reported here. - 9/5/2011
Apixaban may be a safer anti-platelet therapy than existing options
The investigative oral Factor Xa inhibitor apixaban could prevent strokes among atrial fibrillation patients better than current treatments—and may be able to perform that task without a risk of excessive bleeding. - 9/5/2011
Anti-TNF agents do not raise cancer risk in arthritis patients
Finding reassuring since class of drugs has mandated warning on labels about potential risk of cancer - 9/5/2011
Adding rituximab to other biologics may be safe in rheumatoid arthritis
In an open-label study to investigate the safety of combining biologic agents in the treatment of rheumatoid arthritis, researchers found little serious risk when rituximab (Rituxan) was added to other drugs. - 9/5/2011
A golden surgery chair
- 9/5/2011
$3.5-million settlement awarded in birth mishap
A Quebec doctor has been ordered to pay $3.5 million to the family of a severely handicapped 17-year-old whose life was ruined by a botched birth. - 9/1/2011
Suicide: identifying and supporting patients in your practice
Suicide is one of the 10 leading causes of death in Canada. Some estimate that 90% of people who die by suicide are suffering from depression, another mental illness or a substance abuse disorder.(6) It is not unusual, therefore, for people who commit suicide to have been on medications and to have been interacting with a pharmacist. - 9/1/2011
New guidelines on anaphylaxis plug knowledge gap
Guidelines expected to be especially useful in primary care - 8/31/2011
U.S. pharmacy groups join to fight PBM merger
Pharmacy community is vehemently opposing proposed merger between two major pharmacy benefit management companies in the U.S.